The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2017
2023
2022
2021
2020
2019
2018
2016
2015
2013
All years
November 21, 2017
Interim report January – September 2017
November 14, 2017
Promore Pharma Signs Out-licensing Agreement with Transdermal Therapeutic Technologies for its Peptide DPK-060
October 31, 2017
Promore Pharma Signs Agreement with CRO PCG Clinical Services
October 30, 2017
Promore Pharma Completes Extensive European Collaboration Regarding DPK-060
September 21, 2017
Promore Pharma Signs Manufacturing Agreement with APL
September 12, 2017
Promore Pharma presents at the symposium for hard-to-heal wounds in connection with Nordic Life Science Days
August 30, 2017
Interim report January – June 2017
July 4, 2017
Promore Pharma starts trading on Nasdaq First North on 6 July 2017
June 30, 2017
Promore Pharma awaiting approval from Nasdaq First North in next week
June 26, 2017
New share issue in Promore Pharma raises 76 MSEK ahead of listing on Nasdaq First North
June 7, 2017
Promore Pharma Carries Out a Share Issue Prior to Listing on Nasdaq First North
May 19, 2017
Interim report January – March 2017
May 17, 2017
Promore Pharma AB files phase III clinical trial application in India
April 26, 2017
Promore Pharma AB elects Marianne Dicander Alexandersson as New Board Member and outlines plans for IPO
